PharmaShots | Incisive News in 3 Shots

Subscribe Now

Lytix Biopharma

Lytix Biopharma’s LTX-315 Receives EC’s Approval to Initiate P-II (ATLAS-IT-05) Study for Advanced Melanoma in EU

Lytix Biopharma’s LTX-315 Receives EC’s Approval to Initiate P-II (ATLAS-IT-05) Study for Advanced Melanoma in EU

September 7, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us